文献速递主动脉疾病

RelayPlus支架行胸主动脉瘤及穿透性动脉粥样硬化性溃疡腔内修复的中期结局

Midterm outcomes in patients undergoing endovascular repair of thoracic aortic aneurysms and penetrating atherosclerotic ulcers using the RelayPlus stent graft.
PubMed 文献 · J Vasc Surg · 2020-06-19

该前瞻性、多中心、非随机上市后研究纳入45例胸主动脉瘤或穿透性动脉粥样硬化性溃疡患者,使用RelayPlus支架行TEVAR,技术成功率100%,30天TEVAR相关死亡率4.4%,3年免于TEVAR相关死亡率、全因死亡率和再干预率分别为95.6%、84.0%和97.2%。

要点

  • RelayPlus支架治疗胸主动脉瘤和PAU技术成功率达100%,30天TEVAR相关死亡率4.4%。
  • 3年免于TEVAR相关死亡率为95.6%,免于全因死亡率为84.0%,免于再干预率为97.2%。
  • 3年随访中2例I型内漏,其中1例IB型无移位或瘤囊增大,1例IA型伴近端锚定区下移和近端主动脉扩张。

核心结论

  • RelayPlus上市后研究显示围手术期死亡率和并发症率低,支持该装置作为胸主动脉瘤和PAU的安全有效腔内治疗选择。
  • 早期中期随访显示在真实世界实践中持续免于TEVAR相关死亡。

研究设计与样本

  • 前瞻性、多中心、非随机上市后研究,要求使用新手植入者,共纳入45例患者。
  • 患者平均年龄73.5(标准差7.20)岁,56%为降主动脉梭形动脉瘤,44%为囊状动脉瘤或PAU。
  • 主要终点为装置相关不良事件,次要终点为主要不良事件,采用Kaplan-Meier法报告3年结局。

主要发现

  • 技术成功率为100%,30天TEVAR相关死亡率为4.4%(2例死亡:1例休克,1例双侧半球卒中)。
  • 无患者中转开放手术或发生TEVAR后破裂。
  • 30天主要不良事件包括卒中(2.2%)、截瘫(2.2%)和呼吸衰竭(2.2%),共2例患者发生3次事件。
  • 3年免于TEVAR相关死亡率、全因死亡率和再干预率分别为95.6%、84.0%和97.2%。
  • 3年时发生2例I型内漏:1例IB型无移位或瘤囊增大,1例IA型伴近端锚定区下移和近端主动脉扩张。

关键数值与推荐

  • 平均(标准差)近端锚定区、远端锚定区和病变长度分别为38.2(±37)mm、42.1(±28)mm和103.8(±74)mm。
  • 平均(标准差)动脉瘤、近端锚定区和远端锚定区直径分别为53.9(±13)mm、31.3(±4)mm和31.7(±6)mm。

临床怎么用

  • RelayPlus可用于胸主动脉瘤和PAU的TEVAR治疗,围手术期死亡率和并发症率低。
  • 中期随访中TEVAR相关死亡率持续较低,但需继续随访评估内漏和移位的耐久性。

局限性

  • 样本量较小(45例),为非随机研究。
  • 随访时间限于中期(3年),耐久性需更长期评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Relay Thoracic Stent-Graft with Plus Delivery System (RelayPlus; Terumo Aortic, Sunrise, Fla) was designed to handle the curvature and tortuosity of the thoracic aorta. It was approved by the Food and Drug Administration in 2012; the postapproval study was stopped early because of adequate safety and efficacy data, and no difference was identified in experienced vs first-time users of RelayPlus. The purpose of this study was to report real-world outcomes of patients with thoracic aortic aneurysms and penetrating atherosclerotic ulcers (PAUs) undergoing thoracic endovascular aortic repair (TEVAR) with RelayPlus. METHODS: This is a prospective, multicenter, nonrandomized postapproval study that required the use of novice implanters in the United States. Primary and secondary end points included device-related adverse events (deployment failure, conversion to open repair, endoleaks, migration, rupture, and mortality) and major adverse events (stroke, paraplegia/paraparesis, renal failure, respiratory failure, and myocardial infarction), respectively. Continuous and categorical covariates were reported in means or medians and percentages, respectively. Kaplan-Meier survival estimates were used to report long-term TEVAR-related mortality, all-cause mortality, and reinterventions at 3 years. RESULTS: A total of 45 patients with mean age (standard deviation [SD]) of 73.5 (±7.20) years were treated for descending thoracic fusiform aneurysm (56%) or saccular aneurysm/PAU (44%). The patients were predominantly white (80.0%) and male (68.9%). Mean (SD) proximal neck, distal neck, and lesion lengths were 38.2 (±37) mm, 42.1 (±28) mm, and 103.8 (±74) mm, respectively. Mean (SD) aneurysm, proximal neck, and distal neck diameters were 53.9 (±13) mm, 31.3 (±4) mm, and 31.7 (±6) mm, respectively. Technical success was 100%. TEVAR-related mortality at 30 days was 4.4%; two patients died postoperatively, one of shock and the second of bilateral hemispheric stroke. No patient in the study had any conversion to open repair or post-TEVAR rupture. Two patients experienced three major adverse events, which included stroke (2.2%), paraplegia (2.2%), and respiratory failure (2.2%) at 30 days. Three-year freedom from TEVAR-related mortality, all-cause mortality, and reinterventions was 95.6%, 84.0%, and 97.2%, respectively. There were two type I endoleaks at 3 years: one type IB associated with no migration or aneurysm sac increase and one type IA associated with caudal migration of proximal neck and expansion of the proximal aorta. CONCLUSIONS: The RelayPlus postapproval study reported low operative mortality and morbidity and supported use of the device as a safe and effective thoracic aortic aneurysm and PAU endovascular treatment. Early midterm follow-up showed sustained freedom from TEVAR-related mortality in real-world practice. Follow-up continues to evaluate the durability of this endograft.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Malas M, Locham S, Hughes C, et al. Midterm outcomes in patients undergoing endovascular repair of thoracic aortic aneurysms and penetrating atherosclerotic ulcers using the RelayPlus stent graft. J Vasc Surg. 2020. PMID: 32565108. doi:10.1016/j.jvs.2020.05.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。